A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

NCT00073476

Last updated date
Study Location
Pfizer Investigational Site
La Mesa, California, 91942, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Stroke
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40-90 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Males & females age 40-90 years

Enrolled in study within 6 hours of onset of stroke symptoms

Willing to sign informed consent form

No significant disabilities prior to stroke

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Treatment with t-PA (tissue plasminogen activator)


Premorbid modified rankin scale score of 2 or more

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

StrokePERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.
NCT00432796
  1. Halifax, Nova Scotia
  2. Hamilton, Ontario
  3. Hamilton, Ontario
  4. Hamilton, Ontario
  5. Ottawa, Ontario
  6. Montreal, Quebec
  7. Hyderabad, Nampally
  8. New Delhi,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
StrokeAtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
NCT03192215
  1. Birmingham, Alabama
  2. Mobile, Alabama
  3. Phoenix, Arizona
  4. Tucson, Arizona
  5. Little Rock, Arkansas
  6. Castro Valley, California
  7. La Jolla, California
  8. Long Beach, California
  9. Los Alamitos, California
  10. Los Angeles, California
  11. Los Angeles, California
  12. Orange, California
  13. Salinas, California
  14. San Diego, California
  15. San Francisco, California
  16. San Francisco, California
  17. Englewood, Colorado
  18. Grand Junction, Colorado
  19. Hartford, Connecticut
  20. New Haven, Connecticut
  21. Washington, District of Columbia
  22. Washington, District of Columbia
  23. Gainesville, Florida
  24. Jacksonville, Florida
  25. Miami, Florida
  26. Miami, Florida
  27. Miami, Florida
  28. Sarasota, Florida
  29. Tampa, Florida
  30. Atlanta, Georgia
  31. Atlanta, Georgia
  32. Chicago, Illinois
  33. Chicago, Illinois
  34. Chicago, Illinois
  35. Chicago, Illinois
  36. Peoria, Illinois
  37. Springfield, Illinois
  38. Winfield, Illinois
  39. Iowa City, Iowa
  40. Kansas City, Kansas
  41. Lexington, Kentucky
  42. Louisville, Kentucky
  43. New Orleans, Louisiana
  44. Bangor, Maine
  45. Baltimore, Maryland
  46. Boston, Massachusetts
  47. Boston, Massachusetts
  48. Boston, Massachusetts
  49. Boston, Massachusetts
  50. Worcester, Massachusetts
  51. Ann Arbor, Michigan
  52. Detroit, Michigan
  53. Detroit, Michigan
  54. Flint, Michigan
  55. Grand Rapids, Michigan
  56. Mount Clemens, Michigan
  57. Minneapolis, Minnesota
  58. Rochester, Minnesota
  59. Saint Paul, Minnesota
  60. Jackson, Mississippi
  61. Saint Louis, Missouri
  62. Springfield, Missouri
  63. Omaha, Nebraska
  64. Pennington, New Jersey
  65. Albuquerque, New Mexico
  66. Bronx, New York
  67. Brooklyn, New York
  68. Brooklyn, New York
  69. Brooklyn, New York
  70. Brooklyn, New York
  71. Brooklyn, New York
  72. Buffalo, New York
  73. Manhasset, New York
  74. New York, New York
  75. New York, New York
  76. New York, New York
  77. New York, New York
  78. New York, New York
  79. Rochester, New York
  80. Greensboro, North Carolina
  81. Winston-Salem, North Carolina
  82. Cincinnati, Ohio
  83. Cleveland, Ohio
  84. Cleveland, Ohio
  85. Cleveland, Ohio
  86. Columbus, Ohio
  87. Dayton, Ohio
  88. Toledo, Ohio
  89. Oklahoma City, Oklahoma
  90. Portland, Oregon
  91. Allentown, Pennsylvania
  92. Philadelphia, Pennsylvania
  93. Pittsburgh, Pennsylvania
  94. Providence, Rhode Island
  95. Charleston, South Carolina
  96. Columbia, South Carolina
  97. Greenville, South Carolina
  98. Nashville, Tennessee
  99. Dallas, Texas
  100. Houston, Texas
  101. Houston, Texas
  102. Houston, Texas
  103. San Antonio, Texas
  104. Salt Lake City, Utah
  105. Salt Lake City, Utah
  106. Charlottesville, Virginia
  107. Richmond, Virginia
  108. Seattle, Washington
  109. Seattle, Washington
  110. Morgantown, West Virginia
  111. Milwaukee, Wisconsin
  112. La Mesa, California
  113. Los Angeles, California
  114. Los Angeles, California
  115. Sacramento, California
  116. Stanford, California
  117. Honolulu, Hawaii
  118. Burlington, Massachusetts
  119. Saint Louis, Missouri
  120. Asheville, North Carolina
  121. Akron, Ohio
  122. Memphis, Tennessee
  123. Edinburg, Texas
  124. Harlingen, Texas
ALL GENDERS
45 Years+
years
MULTIPLE SITES
StrokeA Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke
NCT00073476
  1. La Mesa, California
  2. Atlanta, Georgia
  3. Fort Wayne, Indiana
  4. Fort Wayne, Indiana
  5. Louisville,, Kentucky
  6. Louisville, Kentucky
  7. Salisbury, North Carolina
  8. Dayton, Ohio
  9. Dayton, Ohio
  10. Dayton, Ohio
  11. Dayton, Ohio
  12. Allentown, Pennsylvania
  13. Philadelphia, Pennsylvania
  14. Tartu,
  15. Bad Neustadt,
  16. Freiburg,
  17. Leipzig,
  18. Luebeck,
  19. Budapest,
  20. Gyor,
  21. Pavia,
  22. Perugia,
  23. Coimbra,
  24. Lisboa,
  25. Singapore,
  26. Singapore,
  27. Santiago de Compostela, Galicia
  28. Madrid,
  29. Madrid,
  30. Zaragoza,
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke
Official Title  ICMJE A Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a 72-Hour Infusion of CP-101,606 in Subjects With Acute Ischemic Stroke.
Brief Summary The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Stroke
Intervention  ICMJE Drug: traxiprodil (CP-101,606)
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Enrollment  ICMJE
 (submitted: June 20, 2006)
300
Original Enrollment  ICMJE Not Provided
Study Completion Date  ICMJE February 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

Males & females age 40-90 years

Enrolled in study within 6 hours of onset of stroke symptoms

Willing to sign informed consent form

No significant disabilities prior to stroke

Exclusion Criteria:

Treatment with t-PA (tissue plasminogen activator)

Premorbid modified rankin scale score of 2 or more

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 40 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Estonia,   Germany,   Hungary,   Italy,   Portugal,   Singapore,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00073476
Other Study ID Numbers  ICMJE A1611005
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP